Health Innovation
4 Repeat-Founder Health Startups With Peer-Reviewed Research
DealBio tracks early-stage health and longevity startups across Europe and North America. These 4 pair repeat-founder experience with peer-reviewed scientific evidence.
- Repeat Founder
- Peer-Reviewed Research
- Academic Founder
Repeat-founder experience and peer-reviewed research test different parts of an early startup. One shows that a founder has built before; the other gives outside scrutiny to the science behind the new venture.
The combination is most useful when both connect directly to what the startup is trying to build now.
At a Glance
- Translation-XSwitzerland2022Autism therapeutics
- AviSia TherapeuticsNetherlands2024Antigen-specific immunotherapy
- Beyond DiagnosticsSwitzerland2026Point-of-care insulin testing
- Constellate ProteomicsNetherlands2025Single-molecule antibody analytics
Developing oral small molecules for core symptoms of genetically defined autism.
- Country
Switzerland- Founded
- 2022
- Sector
- Biotech
- Funding stage
- Seed or earlier
Why Translation-X stands out
Translation-X pairs peer-reviewed autism biology with repeat operating experience. A Nature study showed that MNK1/2 inhibition normalized protein translation, restored oxytocin signalling and improved social novelty responses in a genetic autism mouse model, while co-founder Guido Koch brings more than 25 years in pharma R&D and biotech leadership.
What Translation-X is building
The startup is developing brain-penetrant oral MNK1/2 inhibitors for genetically defined forms of autism, starting with Fragile X syndrome, Phelan-McDermid syndrome and tuberous sclerosis complex.
Developing antigen-specific immunotherapy for type 1 diabetes.
- Country
Netherlands- Founded
- 2024
- Sector
- Biotech
- Funding stage
- Seed or earlier
- Founders
Why AviSia Therapeutics stands out
AviSia combines repeat biotech company-building experience with peer-reviewed glyco-immunology research. Founder Henk Viëtor previously co-founded Skyline Diagnostics and led it through a Series A, while research from CSO Yvette van Kooyk's group showed that sialylated antigens can induce antigen-specific immune tolerance. AviSia also reports three feasibility experiments supporting the AVS-006 mechanism.
What AviSia Therapeutics is building
AVS-006 links proinsulin to an inhibitory glycan designed to restore immune tolerance to beta-cell antigens without broad immunosuppression. The same design can be adapted to other disease-driving antigens.
Building smartphone-read point-of-care tests to verify insulin quality.
- Country
- Switzerland
- Founded
- 2026
- Sector
- Diagnostics
- Funding stage
- Seed or earlier
- Founders
Why Beyond Diagnostics stands out
Beyond Diagnostics pairs repeat-founder execution with peer-reviewed diabetes research. Maren Schinz previously built a diabetes-accessories startup that reached more than 2,000 customers in its first year and co-authored a 2026 study of 104 adults with type 1 diabetes across 19 countries. The startup has since built a functional insulin-activity prototype.
What Beyond Diagnostics is building
LUMIQ is a lateral-flow test designed to estimate remaining insulin activity before injection. A smartphone camera reads the strip and AI converts the optical signal into an estimate of biological activity.
Building single-molecule tools to screen antibody quality earlier in development.
- Country
- Netherlands
- Founded
- 2025
- Sector
- Biotech
- Funding stage
- Seed or earlier
Why Constellate Proteomics stands out
Constellate Proteomics combines a repeat-founder commercial perspective with peer-reviewed single-molecule science. CEO Carlos de Lannoy co-authored the 2024 Nature Nanotechnology paper demonstrating the core protein-fingerprinting method, while Dennis de Beeld previously co-founded ImmunoWars and helped scale it to more than 5,000 copies across 30+ countries. The operational platform is now open for biopharma and CDMO pilots.
What Constellate Proteomics is building
RAYmAb analyses antibodies directly from crude cell-culture samples and is designed to measure titre, glycosylation, aggregation and charge variants earlier in cell-line development.
Deal Sourcing for Investors
Looking for More Startups Like These?
DealBio helps investment teams discover, research, and monitor early-stage healthcare and life sciences startups aligned with their investment criteria.
Investment perspective
Peer-reviewed research can show that the underlying mechanism deserves attention. Repeat-founder experience answers a different question: whether the team has already learned what it takes to turn an idea into an operating company.
The combination becomes most useful when those signals meet at the next execution step. Strong science can justify moving forward, while prior company-building experience can help the team decide how to finance, partner, develop or commercialize what the evidence has opened up.
Methodology
DealBio selected these startups from its database of early-stage health and longevity startups, focusing on businesses with both repeat-founder experience and peer-reviewed research. The selection spans therapeutics, diagnostics and research tools, with emphasis on companies where the evidence connects directly to the product being built.
DealBio builds its Startup Briefs using publicly available company materials, ecosystem sources, market references and professional profiles.